Apomorphine

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.

CHICAGO — Continuous subcutaneous apomorphine infusion reduced “off” time and increased “on” time without troublesome dyskinesia in patients with Parkinson’s disease in the United States, with no new safety signals reported.

Apomorphine sublingual film resulted in greater motor improvement and an increase in responders at earlier time points compared with levodopa, according to results from a study of more than 300 patients with Parkinson’s disease.